COVID-19 Pandemic (Coronavirus)

Pito

305
Supporter
Joined
Apr 30, 2012
Messages
1,020
Reputation
450
Daps
2,517
Reppin
Dade County
Got my second dose yesterday (Moderna at around 2pm est).

arm is sore as shyt but other than that nothing major so far.
 

Mr. Jack Napier

#MambaForever
Supporter
Joined
May 1, 2012
Messages
43,838
Reputation
7,142
Daps
159,972
Reppin
The Empire State
[Redacted]

He's the same guy who said the pandemic was over back in November...

In October, Yeadon wrote a column for the United Kingdom’s Daily Mail newspaper that also appeared on MailOnline, one of the world’s most-visited news websites. It declared that deaths caused by COVID-19, which then totaled about 45,000 in Britain, will soon “fizzle out” and Britons “should immediately be allowed to resume normal life.” Since then, the disease has killed about another 80,000 people in the UK.

That is from a Reuters article

The ex-Pfizer scientist who became an anti-vax hero.
 
Last edited by a moderator:

Slic Ric

All Star
Joined
May 12, 2015
Messages
2,464
Reputation
190
Daps
5,946
Reppin
NYC
So I took 1 tylenol 4 hours after my first dose, reading that doctors are saying NOT to after, is that normal?
 

goatmane

Veteran
Joined
Jan 26, 2017
Messages
16,775
Reputation
2,605
Daps
114,635
South African variant can 'break through' Pfizer vaccine, Israeli study says

South African variant can 'break through' Pfizer vaccine, Israeli study says
By Maayan Lubell

JERUSALEM (Reuters) - The coronavirus variant discovered in South Africa can “break through” Pfizer/BioNTech’s COVID-19 vaccine to some extent, a real-world data study in Israel found, though its prevalence in the country is low and the research has not been peer reviewed.

Slideshow ( 3 images )
The study, released on Saturday, compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated patients with the disease. It matched age and gender, among other characteristics.

The South African variant, B.1.351, was found to make up about 1% of all the COVID-19 cases across all the people studied, according to the study by Tel Aviv University and Israel’s largest healthcare provider, Clalit.

But among patients who had received two doses of the vaccine, the variant’s prevalence rate was eight times higher than those unvaccinated - 5.4% versus 0.7%.

This suggests the vaccine is less effective against the South African variant, compared with the original coronavirus and a variant first identified in Britain that has come to comprise nearly all COVID-19 cases in Israel, the researchers said.

“We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group. This means that the South African variant is able, to some extent, to break through the vaccine’s protection,” said Tel Aviv University’s Adi Stern.

ADVERTISEMENT

The researchers cautioned, though, that the study only had a small sample size of people infected with the South African variant because of its rarity in Israel.

They also said the research was not intended to deduce overall vaccine effectiveness against any variant, since it only looked at people who had already tested positive for COVID-19, not at overall infection rates.

Pfizer and BioNTech could not be immediately reached for comment outside business hours.

The companies said on April 1 that their vaccine was around 91% effective at preventing COVID-19, citing updated trial data that included participants inoculated for up to six months.

In respect to the South African variant, they said that among a group of 800 study volunteers in South Africa, where B.1.351 is widespread, there were nine cases of COVID-19, all of which occurred among participants who got the placebo. Of those nine cases, six were among individuals infected with the South African variant.

ADVERTISEMENT

Some previous studies have indicated that the Pfizer/BioNTech shot was less potent against the B.1.351 variant than against other variants of the coronavirus, but still offered a robust defence.

While the results of the study may cause concern, the low prevalence of the South African strain was encouraging, according to Stern.

“Even if the South African variant does break through the vaccine’s protection, it has not spread widely through the population,” said Stern, adding that the British variant may be “blocking” the spread of the South African strain.

Almost 53% of Israel’s 9.3 million population has received both Pfizer doses. Israel has largely reopened its economy in recent weeks while the pandemic appears to be receding, with infection rates, severe illness and hospitalizations dropping sharply. About a third of Israelis are below the age of 16, which means they are still not eligible for the shot
 
Top